

David Saadoun

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8918282/publications.pdf>

Version: 2024-02-01

243
papers

14,422
citations

12330

69
h-index

24982

109
g-index

248
all docs

248
docs citations

248
times ranked

13844
citing authors

#	ARTICLE	IF	CITATIONS
1	Correspondence on "Impact of COVID-19 pandemic on patients with large-vessels vasculitis in Italy: a monocentric survey". <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e30-e30.	0.9	11
2	Efficacy and safety of TNF- α antagonists and tocilizumab in Takayasu arteritis: multicentre retrospective study of 209 patients. <i>Rheumatology</i> , 2022, 61, 1376-1384.	1.9	26
3	Mast cells drive pathologic vascular lesions in Takayasu arteritis. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 292-301.e3.	2.9	7
4	HCV-related lymphoproliferative disorders in the direct-acting antiviral era: From mixed cryoglobulinaemia to B-cell lymphoma. <i>Journal of Hepatology</i> , 2022, 76, 174-185.	3.7	11
5	Anti-Tumor Necrosis Factor α versus Tocilizumab in the Treatment of Refractory Uveitic Macular Edema. <i>Ophthalmology</i> , 2022, 129, 520-529.	5.2	32
6	Overview of Imaging in Adult- and Childhood-onset Takayasu Arteritis. <i>Journal of Rheumatology</i> , 2022, 49, 346-357.	2.0	2
7	Mortality associated with Behçet's disease in France assessed by multiple-cause-of-death analysis. <i>Clinical Rheumatology</i> , 2022, 41, 1749-1758.	2.2	5
8	Relapse of Hepatitis C Virus Cryoglobulinemic Vasculitis After Sustained Viral Response After Interferon-Free Direct-Acting Antivirals. <i>American Journal of Gastroenterology</i> , 2022, 117, 627-636.	0.4	9
9	Interferon signature in giant cell arteritis aortitis. <i>Journal of Autoimmunity</i> , 2022, 127, 102796.	6.5	14
10	Echocardiography and renin-aldosterone interplay as predictors of death in COVID-19. <i>Archives of Cardiovascular Diseases</i> , 2022, 115, 96-96.	1.6	1
11	Prognostic Factors and Treatment Efficacy in Spinal Cord Sarcoidosis. <i>Neurology</i> , 2022, 98, .	1.1	6
12	Lower Relapses Rate With Infliximab Versus Adalimumab in Sight-Threatening Uveitis: A Multicenter Study of 330 Patients. <i>American Journal of Ophthalmology</i> , 2022, 238, 173-180.	3.3	13
13	Prevalence and clinical features of COVID-19 in a large cohort of 199 patients with sarcoidosis. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 195-196.	0.8	7
14	Reply. <i>Ophthalmology</i> , 2022, , .	5.2	0
15	Cerebrovascular Ischemic Events in Patients With Takayasu Arteritis. <i>Stroke</i> , 2022, 53, 1550-1557.	2.0	12
16	Vascular Behçet's disease: a comparative study from Turkey and France.. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.8	0
17	Hepatitis C virus-related vasculitis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101575.	1.5	5
18	Cytokine profile as a prognostic tool in coronavirus disease 2019. Comment on "Urgent avenues in the treatment of COVID-19: Targeting downstream inflammation to prevent catastrophic syndrome" by Quartuccio et al. <i>Joint Bone Spine</i> . 2020;87:191-193. <i>Joint Bone Spine</i> , 2021, 88, 105074.	1.6	5

#	ARTICLE	IF	CITATIONS
19	Rituximab plus belimumab in non-infectious refractory cryoglobulinemia vasculitis: A pilot study. <i>Journal of Autoimmunity</i> , 2021, 116, 102577.	6.5	19
20	Antiphospholipid antibodies and thrombotic events in COVID-19 patients hospitalized in medicine ward. <i>Autoimmunity Reviews</i> , 2021, 20, 102729.	5.8	26
21	Temporal arteritis in IgG4 related disease. <i>Joint Bone Spine</i> , 2021, 88, 105087.	1.6	6
22	Prevalence of hyposmia and hypogeusia in 390 COVID-19 hospitalized patients and outpatients: a cross-sectional study. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 691-697.	2.9	39
23	Women and Pregnancy in Thromboangiitis Obliterans. <i>Journal of Vascular Research</i> , 2021, 58, 1-3.	1.4	2
24	Medium- and Large-Vessel Vasculitis. <i>Circulation</i> , 2021, 143, 267-282.	1.6	68
25	French recommendations for the management of Behçet's disease. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 352.	2.7	27
26	Regulatory T cell/Th17 balance in the pathogenesis of paediatric Behçet disease. <i>Rheumatology</i> , 2021, 61, 422-429.	1.9	17
27	Extrahepatic Manifestations of Chronic HCV Infection. <i>New England Journal of Medicine</i> , 2021, 384, 1038-1052.	27.0	90
28	Direct oral anticoagulant for venous thrombosis in Behçet's syndrome. <i>Autoimmunity Reviews</i> , 2021, 20, 102783.	5.8	7
29	Old and New Challenges in Uveitis Associated with Behçet's Disease. <i>Journal of Clinical Medicine</i> , 2021, 10, 2318.	2.4	6
30	French recommendations for the management of Takayasu's arteritis. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 311.	2.7	21
31	Pharmacokinetics and pharmacodynamics of hydroxychloroquine in hospitalized patients with COVID-19. <i>Therapie</i> , 2021, 76, 285-295.	1.0	8
32	Perspectives for immunotherapy in noninfectious immune mediated uveitis. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 977-989.	3.0	5
33	Immune checkpoint inhibitors for progressive multifocal leukoencephalopathy: a new gold standard?. <i>Journal of Neurology</i> , 2021, 268, 2458-2465.	3.6	14
34	Correlation between Ultra-Wide-Field Retinal Imaging Findings and Vascular Supra-Aortic Changes in Takayasu Arteritis. <i>Journal of Clinical Medicine</i> , 2021, 10, 4916.	2.4	5
35	Prevalence and clinical features of COVID-19 in a large cohort of 199 patients with sarcoidosis. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.8	1
36	Rituximab-associated Vasculitis Flare: Incidence, Predictors, and Outcome. <i>Journal of Rheumatology</i> , 2020, 47, 896-902.	2.0	21

#	ARTICLE	IF	CITATIONS
37	Systemic lupus erythematosus associated with thymoma: A fifteen-year observational study in France. <i>Autoimmunity Reviews</i> , 2020, 19, 102464.	5.8	5
38	Development of a multivariate prediction model of intensive care unit transfer or death: A French prospective cohort study of hospitalized COVID-19 patients. <i>PLoS ONE</i> , 2020, 15, e0240711.	2.5	54
39	Reactive oxygen species and TNF- α : the interplay between obstructive sleep apnea and Behçet's disease. <i>Sleep and Breathing</i> , 2020, 25, 1553-1554.	1.7	0
40	Risk factors for vascular liver diseases. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020, 44, 410-419.	1.5	4
41	Response. <i>Chest</i> , 2020, 158, 2705-2706.	0.8	1
42	Emerging Molecular Targets for the Treatment of Refractory Sarcoidosis. <i>Frontiers in Medicine</i> , 2020, 7, 594133.	2.6	8
43	Biotherapies in Uveitis. <i>Journal of Clinical Medicine</i> , 2020, 9, 3599.	2.4	30
44	A strobe multicenter descriptive study of 55 infectious aortitis. <i>Medicine (United States)</i> , 2020, 99, e22422.	1.0	11
45	Treatment of chronic hepatitis C-associated cryoglobulinemia vasculitis at the era of direct-acting antivirals. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482094261.	3.2	21
46	Pregnancy issues in Takayasu arteritis. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 911-914.	3.4	12
47	Tocilizumab in treatment-naïve patients with Takayasu arteritis: TOCITAKA French prospective multicenter open-labeled trial. <i>Arthritis Research and Therapy</i> , 2020, 22, 218.	3.5	31
48	Cardiac sarcoidosis: A long term follow up study. <i>PLoS ONE</i> , 2020, 15, e0238391.	2.5	32
49	Correspondance on the clinical characteristics and genetic analyses of 187 patients with undefined autoinflammatory diseases. <i>Annals of the Rheumatic Diseases</i> , 2020, , annrhumdis-2020-219566.	0.9	0
50	Neutrophil-Platelet and Monocyte-Platelet Aggregates in COVID-19 Patients. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1733-1735.	3.4	41
51	Strategies to prevent persistent or relapsed mixed cryoglobulinemia. <i>Expert Opinion on Orphan Drugs</i> , 2020, 8, 137-143.	0.8	2
52	Factors influencing the recurrence of arterial involvement after surgical repair in Behçet disease. <i>Journal of Vascular Surgery</i> , 2020, 72, 1761-1769.	1.1	16
53	Risk Factors and Prevention of <i>Pneumocystis jirovecii</i> Pneumonia in Patients With Autoimmune and Inflammatory Diseases. <i>Chest</i> , 2020, 158, 2323-2332.	0.8	58
54	Cryoglobulinemia after the era of chronic hepatitis C infection. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 695-700.	3.4	23

#	ARTICLE	IF	CITATIONS
55	Expert opinion on the management and follow-up of uveitis patients during SARS-CoV-2 outbreak. Expert Review of Clinical Immunology, 2020, 16, 651-657.	3.0	3
56	Long-Term Outcome and Prognosis Factors of Isolated Aortitis. Circulation, 2020, 142, 92-94.	1.6	22
57	Evaluating the cost-consequence of a standardized strategy for the etiological diagnosis of uveitis (ULISSE study). PLoS ONE, 2020, 15, e0228918.	2.5	4
58	Prognosis of large vessel involvement in large vessel vasculitis. Journal of Autoimmunity, 2020, 108, 102419.	6.5	17
59	Targeting JAK/STAT pathway in Takayasu's arteritis. Annals of the Rheumatic Diseases, 2020, 79, 951-959.	0.9	56
60	Evolving spectrum of drug-induced uveitis at the era of immune checkpoint inhibitors results from the WHO's pharmacovigilance database. Journal of Autoimmunity, 2020, 111, 102454.	6.5	11
61	Immunomodulatory role of Interleukin-33 in large vessel vasculitis. Scientific Reports, 2020, 10, 6405.	3.3	11
62	Apremilast in Refractory Behçet's Syndrome: A Multicenter Observational Study. Frontiers in Immunology, 2020, 11, 626792.	4.8	12
63	Risk factors for hydroxychloroquine retinopathy in systemic lupus erythematosus: a case-control study with hydroxychloroquine blood-level analysis. Rheumatology, 2020, 59, 3807-3816.	1.9	24
64	Performance of serum apolipoprotein-A1 as a sentinel of Covid-19. PLoS ONE, 2020, 15, e0242306.	2.5	10
65	The Prognosis of Behçet Syndrome. , 2020, , 243-260.		0
66	Title is missing!. , 2020, 15, e0240711.		0
67	Title is missing!. , 2020, 15, e0240711.		0
68	Title is missing!. , 2020, 15, e0240711.		0
69	Title is missing!. , 2020, 15, e0240711.		0
70	Long-term Efficacy of Interferon-Free Antiviral Treatment Regimens in Patients With Hepatitis C Virus-Associated Cryoglobulinemia Vasculitis. Clinical Gastroenterology and Hepatology, 2019, 17, 518-526.	4.4	63
71	Management of skin, mucosa and joint involvement of Behçet's syndrome: A systematic review for update of the EULAR recommendations for the management of Behçet's syndrome. Seminars in Arthritis and Rheumatism, 2019, 48, 752-762.	3.4	56
72	Overall survival and mortality risk factors in Takayasu's arteritis: A multicenter study of 318 patients. Journal of Autoimmunity, 2019, 96, 35-39.	6.5	61

#	ARTICLE	IF	CITATIONS
73	Prognostic Factors in Anti-glomerular Basement Membrane Disease: A Multicenter Study of 119 Patients. <i>Frontiers in Immunology</i> , 2019, 10, 1665.	4.8	31
74	Neuroinflammatory disorders and mastocytosis: A possible association?. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 2878-2881.e1.	3.8	2
75	TLR9 signalling in HCV-associated atypical memory B cells triggers Th1 and rheumatoid factor autoantibody responses. <i>Journal of Hepatology</i> , 2019, 71, 908-919.	3.7	23
76	Osseous sarcoidosis: A multicenter retrospective case-control study of 48 patients. <i>Joint Bone Spine</i> , 2019, 86, 789-793.	1.6	27
77	Different patterns and specific outcomes of large-vessel involvements in giant cell arteritis. <i>Journal of Autoimmunity</i> , 2019, 103, 102283.	6.5	36
78	Critical role of neutrophil extracellular traps (NETs) in patients with Behçet's disease. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1274-1282.	0.9	96
79	Absence of HCV RNA in serum and cryoprecipitate of patients with persisting mixed cryoglobulinaemia vasculitis after direct-acting antiviral agents. <i>GastroHep</i> , 2019, 1, 134-137.	0.6	1
80	Long-term Outcome of Ustekinumab Therapy for Behçet's Disease. <i>Arthritis and Rheumatology</i> , 2019, 71, 1727-1732.	5.6	51
81	Expert opinion on the use of biological therapy in non-infectious uveitis. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 477-490.	3.1	51
82	Corticosteroids and immunosuppressive agents for idiopathic recurrent pericarditis. <i>Autoimmunity Reviews</i> , 2019, 18, 621-626.	5.8	12
83	Cryoglobulinemia: An update in 2019. <i>Joint Bone Spine</i> , 2019, 86, 707-713.	1.6	88
84	Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 209-217.	0.9	273
85	Fluorescein and OCT Angiography Features of Takayasu Disease. <i>Ocular Immunology and Inflammation</i> , 2019, 27, 774-780.	1.8	9
86	Neuro-ophthalmological manifestations of Behçet's disease. <i>British Journal of Ophthalmology</i> , 2019, 103, 83-87.	3.9	15
87	Efficacy of tocilizumab in Takayasu arteritis: Multicenter retrospective study of 46 patients. <i>Journal of Autoimmunity</i> , 2018, 91, 55-60.	6.5	59
88	2018 update of the EULAR recommendations for the management of Behçet's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrheumdis-2018-213225.	0.9	442
89	Large-vessel involvement and aortic dilation in giant-cell arteritis. A multicenter study of 549 patients. <i>Autoimmunity Reviews</i> , 2018, 17, 391-398.	5.8	97
90	Contribution of diagnostic tests for the etiological assessment of uveitis, data from the ULISSE study (Uveitis: Clinical and medicoeconomic evaluation of a standardized strategy of the etiological) <i>Tj ETQ0 0 0 rgBT /Overlock 105 Tf 50 57</i>		

#	ARTICLE	IF	CITATIONS
91	Efficacy and safety of rituximab for systemic lupus erythematosus-associated immune cytopenias: A multicenter retrospective cohort study of 71 adults. <i>American Journal of Hematology</i> , 2018, 93, 424-429.	4.1	56
92	Large-vessel vasculitis in human immunodeficiency virus-infected patients. <i>Journal of Vascular Surgery</i> , 2018, 67, 1501-1511.	1.1	18
93	Impact of sustained virological response on the extrahepatic manifestations of chronic hepatitis C: a meta-analysis. <i>Cut</i> , 2018, 67, 2025-2034.	12.1	104
94	Accumulation of Antigen-Driven Lymphoproliferations in Complement Receptor 2/CD21 ^{low} B Cells From Patients With Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , 2018, 70, 298-307.	5.6	24
95	Sarcoidosis with Takayasu arteritis: a model of overlapping granulomatosis. A report of seven cases and literature review. <i>International Journal of Rheumatic Diseases</i> , 2018, 21, 740-745.	1.9	20
96	Clinical and multi-omics cross-phenotyping of patients with autoimmune and autoinflammatory diseases: the observational TRANSIMMUNOM protocol. <i>BMJ Open</i> , 2018, 8, e021037.	1.9	17
97	Long-Term Outcome and Prognostic Factors of Complications in Thromboangiitis Obliterans (Buerger's Disease): A Multicenter Study of 224 Patients. <i>Journal of the American Heart Association</i> , 2018, 7, e010677.	3.7	40
98	Cryoglobulinaemia. <i>Nature Reviews Disease Primers</i> , 2018, 4, 11.	30.5	143
99	Grazoprevir plus elbasvir in HCV genotype-1 or -4 infected patients with stage 4/5 severe chronic kidney disease is safe and effective. <i>Kidney International</i> , 2018, 94, 206-213.	5.2	18
100	Management of major organ involvement of Behçet's syndrome: a systematic review for update of the EULAR recommendations. <i>Rheumatology</i> , 2018, 57, 2200-2212.	1.9	89
101	Cryoglobulinemic Vasculitis. , 2018, , 355-363.		0
102	Response to: Cryoglobulinemic vasculitis in the era of direct-acting antiviral drug. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, e6.	0.9	0
103	Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection. <i>Journal of Hepatology</i> , 2017, 66, 1282-1299.	3.7	73
104	Efficacy and safety of tumor necrosis factor antagonists in refractory sarcoidosis: A multicenter study of 132 patients. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 288-294.	3.4	81
105	Direct-Acting Antiviral Therapy Restores Immune Tolerance to Patients With Hepatitis C Virus-Induced Cryoglobulinemia Vasculitis. <i>Gastroenterology</i> , 2017, 152, 2052-2062.e2.	1.3	81
106	New insights on tuberculous aortitis. <i>Journal of Vascular Surgery</i> , 2017, 66, 209-215.	1.1	30
107	Rheumatologic Manifestations of Hepatitis C Virus Infection. <i>Clinics in Liver Disease</i> , 2017, 21, 455-464.	2.1	17
108	International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , 2017, 16, 650-657.	5.8	32

#	ARTICLE	IF	CITATIONS
109	Ustekinumab for Behçet's disease. <i>Journal of Autoimmunity</i> , 2017, 82, 41-46.	6.5	58
110	Effectiveness and cost of hepatitis C virus cryoglobulinaemia vasculitis treatment: From interferon-based to direct-acting antivirals era. <i>Liver International</i> , 2017, 37, 1805-1813.	3.9	26
111	Reply. <i>American Journal of Ophthalmology</i> , 2017, 179, 208-209.	3.3	0
112	Cardiac sarcoidosis: Diagnosis, therapeutic management and prognostic factors. <i>Archives of Cardiovascular Diseases</i> , 2017, 110, 456-465.	1.6	35
113	Randomized Controlled Trial Evaluating a Standardized Strategy for Uveitis Etiologic Diagnosis (ULISSE). <i>American Journal of Ophthalmology</i> , 2017, 178, 176-185.	3.3	69
114	Cryoglobulinemia vasculitis: how to handle. <i>Current Opinion in Rheumatology</i> , 2017, 29, 343-347.	4.3	17
115	Prise en charge de la maladie de Takayasu. <i>Revue Du Rhumatisme Monographies</i> , 2017, 84, 229-235.	0.0	3
116	International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement. <i>Autoimmunity Reviews</i> , 2017, 16, 523-541.	5.8	87
117	Efficacy and Safety of Sofosbuvir Plus Daclatasvir for Treatment of HCV-Associated Cryoglobulinemia Vasculitis. <i>Gastroenterology</i> , 2017, 153, 49-52.e5.	1.3	125
118	Uveitis: Diagnostic work-up. A literature review and recommendations from an expert committee. <i>Autoimmunity Reviews</i> , 2017, 16, 1254-1264.	5.8	93
119	Association of Prognostic Factors and Immunosuppressive Treatment With Long-term Outcomes in Neurosarcoidosis. <i>JAMA Neurology</i> , 2017, 74, 1336.	9.0	76
120	Ophthalmic manifestations in IgG4-related disease. <i>Medicine (United States)</i> , 2017, 96, e6205.	1.0	65
121	Brief Report: Defective Early B Cell Tolerance Checkpoints in Sjögren's Syndrome Patients. <i>Arthritis and Rheumatology</i> , 2017, 69, 2203-2208.	5.6	40
122	Investigational drugs in systemic vasculitis. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 1049-1061.	4.1	5
123	Long-Term Outcomes and Prognostic Factors of Complications in Takayasu Arteritis. <i>Circulation</i> , 2017, 136, 1114-1122.	1.6	161
124	Long-term Efficacy of Interferon in Severe Uveitis Associated with Behçet Disease. <i>Ocular Immunology and Inflammation</i> , 2017, 25, 76-84.	1.8	46
125	Efficacy and safety of TNF antagonists in ocular sarcoidosis: data from the French registry STAT. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2017, 34, 74-80.	0.2	8
126	Infliximab Versus Adalimumab in the Treatment of Refractory Inflammatory Uveitis: A Multicenter Study From the French Uveitis Network. <i>Arthritis and Rheumatology</i> , 2016, 68, 1522-1530.	5.6	131

#	ARTICLE	IF	CITATIONS
127	Clinicopathologic characteristics, treatment, and outcomes of tubulointerstitial nephritis and uveitis syndrome in adults. <i>Medicine (United States)</i> , 2016, 95, e3964.	1.0	30
128	Variability in the efficacy of the IL1 receptor antagonist anakinra for treating Erdheim-Chester disease. <i>Blood</i> , 2016, 127, 1509-1512.	1.4	49
129	Shrinking lung syndrome associated with systemic lupus erythematosus: A multicenter collaborative study of 15 new cases and a review of the 155 cases in the literature focusing on treatment response and long-term outcomes. <i>Autoimmunity Reviews</i> , 2016, 15, 994-1000.	5.8	48
130	International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement. <i>Autoimmunity Reviews</i> , 2016, 15, 1145-1160.	5.8	87
131	Moving towards new treatments for vasculitis. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 239-242.	2.4	1
132	Efficacy of Anti-TNF α in Severe and Refractory Neuro-Behcet Disease. <i>Medicine (United States)</i> , 2016, 95, e3550.	1.0	43
133	Extrahepatic manifestations of chronic hepatitis C virus infection. <i>Therapeutic Advances in Infectious Disease</i> , 2016, 3, 3-14.	1.8	176
134	Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1777-1782.	0.9	136
135	Dermatomyositis With or Without Anti-Melanoma Differentiation-Associated Gene 5 Antibodies. <i>American Journal of Pathology</i> , 2016, 186, 691-700.	3.8	78
136	Behçet's disease physiopathology: a contemporary review. <i>Autoimmunity Highlights</i> , 2016, 7, 4.	3.9	155
137	Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current <sc>IFN</sc>-free treatment and future perspectives. <i>Liver International</i> , 2016, 36, 47-57.	3.9	193
138	Spectrum and Prognosis of Noninfectious Renal Mixed Cryoglobulinemic GN. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 1213-1224.	6.1	44
139	Myocarditis in Patients With Antisynthetase Syndrome. <i>Medicine (United States)</i> , 2015, 94, e798.	1.0	47
140	Cryoglobulinemia vasculitis. <i>Hematologie</i> , 2015, 21, 193-197.	0.0	0
141	Rituximab in anti-GBM disease: A retrospective study of 8 patients. <i>Journal of Autoimmunity</i> , 2015, 60, 74-79.	6.5	84
142	IFN α induces IL-10 production and tilt the balance between Th1 and Th17 in Behçet disease. <i>Autoimmunity Reviews</i> , 2015, 14, 370-375.	5.8	50
143	Effector T Cells Boost Regulatory T Cell Expansion by IL-2, TNF, OX40, and Plasmacytoid Dendritic Cells Depending on the Immune Context. <i>Journal of Immunology</i> , 2015, 194, 999-1010.	0.8	38
144	Safety and efficacy of oral direct inhibitors of thrombin and factor Xa in antiphospholipid syndrome. <i>Autoimmunity Reviews</i> , 2015, 14, 680-685.	5.8	58

#	ARTICLE	IF	CITATIONS
145	Cryoglobulinemia Vasculitis. American Journal of Medicine, 2015, 128, 950-955.	1.5	229
146	Potential of Pegylated Interferon Alpha-2a in Behçet Uveitis: A Report of Five Cases. Ocular Immunology and Inflammation, 2015, 24, 1-4.	1.8	13
147	Efficacy of Biological-Targeted Treatments in Takayasu Arteritis. Circulation, 2015, 132, 1693-1700.	1.6	157
148	PegIFN±/ribavirin/protease inhibitor combination in severe hepatitis C virus-associated mixed cryoglobulinemia vasculitis. Journal of Hepatology, 2015, 62, 24-30.	3.7	86
149	Long-term outcome of infliximab in severe chronic and refractory systemic sarcoidosis: a report of 16 cases. Clinical and Experimental Rheumatology, 2015, 33, 509-15.	0.8	18
150	Translation Strategy for the Qualification of Drug-induced Vascular Injury Biomarkers. Toxicologic Pathology, 2014, 42, 658-671.	1.8	13
151	CD21 ^{low} Marginal Zone B Cells Highly Express Fc Receptor-like 5 Protein and Are Killed by Anti-Fc Receptor-like 5 Immunotoxins in Hepatitis C Virus-Associated Mixed Cryoglobulinemia Vasculitis. Arthritis and Rheumatology, 2014, 66, 433-443.	5.6	16
152	Behcet's disease in budd-chiari syndrome. Orphanet Journal of Rare Diseases, 2014, 9, 104.	2.7	57
153	Pulmonary Fibrosis in Antineutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis. Medicine (United States), 2014, 93, 340-349.	1.0	122
154	Serum biomarker signature identifies patients with B-cell non-Hodgkin lymphoma associated with cryoglobulinemia vasculitis in chronic HCV infection. Autoimmunity Reviews, 2014, 13, 319-326.	5.8	20
155	Central nervous system angitis: a series of 31 patients. Clinical Rheumatology, 2014, 33, 105-110.	2.2	21
156	Findings of Cardiac Magnetic Resonance Imaging in Asymptomatic Myocardial Ischemic Disease in Takayasu Arteritis. American Journal of Cardiology, 2014, 113, 881-887.	1.6	30
157	Biotherapies in Behçet's disease. Autoimmunity Reviews, 2014, 13, 762-769.	5.8	26
158	Long-Term Outcome of Neuro-Behçet's Disease. Arthritis and Rheumatology, 2014, 66, 1306-1314.	5.6	102
159	Current and future therapeutic strategies for treating mixed cryoglobulinemia. Expert Opinion on Orphan Drugs, 2014, 2, 381-390.	0.8	1
160	Hepatitis C virus-induced vasculitis: therapeutic options. Annals of the Rheumatic Diseases, 2014, 73, 24-30.	0.9	56
161	Systemic sclerosis and prevalence of monoclonal immunoglobulin. Autoimmunity Reviews, 2014, 13, 1189-1194.	5.8	9
162	Peg-IFN±/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24. Annals of the Rheumatic Diseases, 2014, 73, 831-837.	0.9	62

#	ARTICLE	IF	CITATIONS
163	HCV-associated cryoglobulinemic vasculitis: triple/dual antiviral treatment and/or rituximab? Reply to the comment by Ignatova et al. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, e59-e59.	0.9	4
164	Ethnicity and association with disease manifestations and mortality in Behçet's disease. <i>Orphanet Journal of Rare Diseases</i> , 2014, 9, 42.	2.7	52
165	Hydroxychloroquine-Induced Pigmentation in Patients With Systemic Lupus Erythematosus. <i>JAMA Dermatology</i> , 2013, 149, 935.	4.1	91
166	¹⁸ F-fluorodeoxyglucose-positron emission tomography scanning is a useful tool for therapy evaluation of arterial aneurysm in Behçet's disease. <i>Joint Bone Spine</i> , 2013, 80, 420-423.	1.6	15
167	Catastrophic antiphospholipid syndrome and pregnancy: an experience of 13 cases. <i>Rheumatology</i> , 2013, 52, 1635-1641.	1.9	56
168	Behçet's Disease and Pregnancy. <i>Arthritis and Rheumatism</i> , 2013, 65, 2450-2456.	6.7	60
169	Small vessel involvement in Takayasu's arteritis. <i>Autoimmunity Reviews</i> , 2013, 12, 355-362.	5.8	41
170	Hepatitis C Virus Infection, Mixed Cryoglobulinemia, and Kidney Disease. <i>American Journal of Kidney Diseases</i> , 2013, 61, 623-637.	1.9	124
171	La tomographie par Émission de positons au ¹⁸ F-fluorodÉoxyglucose permet lâÉvaluation des anÉvrismes artÉriels dans la maladie de Behçet. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2013, 80, 308-311.	0.0	0
172	L11. Hepatitis C virus mixed cryoglobulinemia vasculitis: Therapeutic options. <i>Presse Medicale</i> , 2013, 42, 523-527.	1.9	4
173	Presentation and Prognosis of Cardiac Involvement in Hepatitis C Virus-Related Vasculitis. <i>American Journal of Cardiology</i> , 2013, 111, 265-272.	1.6	43
174	Myocardial Perfusion Imaging in Takayasu Arteritis. <i>Journal of Rheumatology</i> , 2013, 40, 2052-2060.	2.0	14
175	Serum Immunoglobulin Free Light Chain Assessment in IgG4-Related Disease. <i>International Journal of Rheumatology</i> , 2013, 2013, 1-6.	1.6	17
176	Reply. <i>Arthritis and Rheumatism</i> , 2013, 65, 3007-3008.	6.7	1
177	Approaches to immunosuppression in Behçet's disease. <i>Immunotherapy</i> , 2013, 5, 743-754.	2.0	13
178	Sjögren Syndrome-Associated Small Fiber Neuropathy. <i>Medicine (United States)</i> , 2013, 92, e10-e18.	1.0	51
179	The Spectrum of Type I Cryoglobulinemia Vasculitis. <i>Medicine (United States)</i> , 2013, 92, 61-68.	1.0	150
180	CVID-associated TAC1 mutations affect autoreactive B cell selection and activation. <i>Journal of Clinical Investigation</i> , 2013, 123, 4283-4293.	8.2	153

#	ARTICLE	IF	CITATIONS
181	Virus-Associated Vasculitides: An Update. <i>Current Immunology Reviews</i> , 2013, 9, 2-12.	1.2	2
182	Retrospective Analysis of Surgery Versus Endovascular Intervention in Takayasu Arteritis. <i>Circulation</i> , 2012, 125, 813-819.	1.6	238
183	Low 25-hydroxyvitamin D serum levels correlate with the presence of extra-hepatic manifestations in chronic hepatitis C virus infection. <i>Rheumatology</i> , 2012, 51, 2083-2090.	1.9	23
184	Pseudotumoural presentation of neuro-Behcet's disease: case series and review of literature. <i>Rheumatology</i> , 2012, 51, 1216-1225.	1.9	45
185	Long-Term Outcome of Arterial Lesions in Behçet Disease. <i>Medicine (United States)</i> , 2012, 91, 18-24.	1.0	175
186	Spectrum of Cardiac Lesions in Behçet Disease. <i>Medicine (United States)</i> , 2012, 91, 25-34.	1.0	199
187	Interleukin 21 Correlates with T Cell and B Cell Subset Alterations in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2012, 39, 1819-1828.	2.0	100
188	New insights into the pathogenesis of Behçet's disease. <i>Autoimmunity Reviews</i> , 2012, 11, 687-698.	5.8	255
189	Behçet's disease. <i>Orphanet Journal of Rare Diseases</i> , 2012, 7, 20.	2.7	125
190	Restoration of regulatory and effector T cell balance and B cell homeostasis in systemic lupus erythematosus patients through vitamin D supplementation. <i>Arthritis Research and Therapy</i> , 2012, 14, R221.	3.5	156
191	Interleukin-21 modulates Th1 and Th17 responses in giant cell arteritis. <i>Arthritis and Rheumatism</i> , 2012, 64, 2001-2011.	6.7	147
192	Anti TNF- α in refractory Takayasu's arteritis: Cases series and review of the literature. <i>Autoimmunity Reviews</i> , 2012, 11, 678-684.	5.8	132
193	Critical role of IL-21 in modulating TH17 and regulatory T cells in Behçet disease. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 128, 655-664.	2.9	196
194	Virus-Associated Vasculitides. <i>Current Immunology Reviews</i> , 2011, 7, 443-451.	1.2	1
195	Prognostic factors in patients with hepatitis C virus infection and systemic vasculitis. <i>Arthritis and Rheumatism</i> , 2011, 63, 1748-1757.	6.7	95
196	Prevalence and clinical significance of cryofibrinogenaemia in patients with renal disorders. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 3577-3581.	0.7	13
197	Regulatory T-Cell Responses to Low-Dose Interleukin-2 in HCV-Induced Vasculitis. <i>New England Journal of Medicine</i> , 2011, 365, 2067-2077.	27.0	683
198	Systemic Vasculitis in Patients with Hepatitis C Virus Infection with and without Detectable Mixed Cryoglobulinemia. <i>Journal of Rheumatology</i> , 2011, 38, 104-110.	2.0	23

#	ARTICLE	IF	CITATIONS
199	Interleukin-25: Key Regulator of Inflammatory and Autoimmune Diseases. <i>Current Pharmaceutical Design</i> , 2011, 17, 3781-3785.	1.9	29
200	Peripheral Neuropathies Associated With Primary Sjögren Syndrome. <i>Medicine (United States)</i> , 2011, 90, 133-138.	1.0	94
201	Expansion of Functionally Anergic CD21 ^{low} Marginal Zone-like B Cell Clones in Hepatitis C Virus Infection-Related Autoimmunity. <i>Journal of Immunology</i> , 2011, 187, 6550-6563.	0.8	89
202	The PTPN22 allele encoding an R620W variant interferes with the removal of developing autoreactive B cells in humans. <i>Journal of Clinical Investigation</i> , 2011, 121, 3635-3644.	8.2	259
203	Complement receptor 2/CD21 ⁺ human naive B cells contain mostly autoreactive unresponsive clones. <i>Blood</i> , 2010, 115, 5026-5036.	1.4	399
204	Rituximab plus Peg-interferon- α /ribavirin compared with Peg-interferon- α /ribavirin in hepatitis C-related mixed cryoglobulinemia. <i>Blood</i> , 2010, 116, 326-334.	1.4	248
205	Interleukin-25: a cytokine linking eosinophils and adaptive immunity in Churg-Strauss syndrome. <i>Blood</i> , 2010, 116, 4523-4531.	1.4	126
206	Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin. <i>Liver International</i> , 2010, 30, 1259-1269.	3.9	139
207	Surrogate markers of B cell non-Hodgkin's lymphoma in patients with hepatitis C virus-related cryoglobulinaemia vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 2177-2180.	0.9	19
208	Presentation and outcome of gastrointestinal involvement in hepatitis C virus-related systemic vasculitis: a case-control study from a single-centre cohort of 163 patients. <i>Gut</i> , 2010, 59, 1709-1715.	12.1	28
209	Causes and Predictive Factors of Mortality in a Cohort of Patients with Hepatitis C Virus-related Cryoglobulinemic Vasculitis Treated with Antiviral Therapy. <i>Journal of Rheumatology</i> , 2010, 37, 615-621.	2.0	61
210	Pathogenic T cells have a paradoxical protective effect in murine autoimmune diabetes by boosting Tregs. <i>Journal of Clinical Investigation</i> , 2010, 120, 4558-4568.	8.2	154
211	Clinical and Morphologic Spectrum of Renal Involvement in Patients With Mixed Cryoglobulinemia Without Evidence of Hepatitis C Virus Infection. <i>Medicine (United States)</i> , 2009, 88, 341-348.	1.0	79
212	Efficacy and tolerability of rituximab with or without PEGylated interferon α 2b plus ribavirin in severe hepatitis C virus-related vasculitis: A long-term followup study of thirty-two patients. <i>Arthritis and Rheumatism</i> , 2009, 60, 2531-2540.	6.7	99
213	Cryofibrinogenemia: New Insights into Clinical and Pathogenic Features. <i>American Journal of Medicine</i> , 2009, 122, 1128-1135.	1.5	73
214	Hepatitis C Virus Infection Induced Vasculitis. <i>Clinical Reviews in Allergy and Immunology</i> , 2008, 35, 30-39.	6.5	35
215	Relapse of hepatitis C virus-associated mixed cryoglobulinemia vasculitis in patients with sustained viral response. <i>Arthritis and Rheumatism</i> , 2008, 58, 604-611.	6.7	115
216	Correlation of clinical and virologic responses to antiviral treatment and regulatory T cell evolution in patients with hepatitis C virus-induced mixed cryoglobulinemia vasculitis. <i>Arthritis and Rheumatism</i> , 2008, 58, 2897-2907.	6.7	37

#	ARTICLE	IF	CITATIONS
217	Cryofibrinogen in Patients with Hepatitis C Virus Infection. <i>American Journal of Medicine</i> , 2008, 121, 624-631.	1.5	15
218	Occult Hepatitis C Virus Infection Revisited with Ultrasensitive Real-Time PCR Assay. <i>Journal of Clinical Microbiology</i> , 2008, 46, 2106-2108.	3.9	52
219	Restoration of peripheral immune homeostasis after rituximab in mixed cryoglobulinemia vasculitis. <i>Blood</i> , 2008, 111, 5334-5341.	1.4	101
220	Treatment of hepatitis C-associated mixed cryoglobulinemia vasculitis. <i>Current Opinion in Rheumatology</i> , 2008, 20, 23-28.	4.3	91
221	Role of matrix metalloproteinases, proinflammatory cytokines, and oxidative stress-derived molecules in hepatitis C virus-associated mixed cryoglobulinemia vasculitis neuropathy. <i>Arthritis and Rheumatism</i> , 2007, 56, 1315-1324.	6.7	28
222	The pathophysiology of HCV induced B-cell clonal disorders. <i>Autoimmunity Reviews</i> , 2007, 6, 581-587.	5.8	75
223	Hepatitis C virus eradication followed by HBeAg to anti-HBe seroconversion after pegylated interferon- α 2b plus ribavirin treatment in a patient with hepatitis B and C coinfection. <i>European Journal of Gastroenterology and Hepatology</i> , 2006, 18, 1019-1022.	1.6	16
224	Cryoglobulinaemia vasculitis in patients coinfecting with HIV and hepatitis C virus. <i>Aids</i> , 2006, 20, 871-877.	2.2	19
225	Antiviral therapy for hepatitis C virus-associated mixed cryoglobulinemia vasculitis: A long-term followup study. <i>Arthritis and Rheumatism</i> , 2006, 54, 3696-3706.	6.7	227
226	Cryoglobulinemia is associated with steatosis and fibrosis in chronic hepatitis C. <i>Hepatology</i> , 2006, 43, 1337-1345.	7.3	88
227	Increased Risks of Lymphoma and Death Among Patients With Non-Hepatitis C Virus-Related Mixed Cryoglobulinemia. <i>Archives of Internal Medicine</i> , 2006, 166, 2101.	3.8	131
228	Treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: anti-viral therapy vs rituximab. <i>Rheumatology</i> , 2006, 45, 783-784.	1.9	3
229	Regulatory and Effector T Cell Activation Levels Are Prime Determinants of In Vivo Immune Regulation. <i>Journal of Immunology</i> , 2006, 177, 2167-2174.	0.8	70
230	Manifestations extra hépatiques liées à l'infection chronique par le virus de l'hépatite C et leurs traitements.. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2006, 190, 123-137.	0.0	0
231	Hepatitis C virus infection and mixed cryoglobulinaemia vasculitis: a review of neurological complications. <i>Aids</i> , 2005, 19, S128-S134.	2.2	65
232	Splenic lymphoma with villous lymphocytes, associated with type II cryoglobulinemia and HCV infection: a new entity?. <i>Blood</i> , 2005, 105, 74-76.	1.4	200
233	PEGylated interferon α 2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. <i>Arthritis and Rheumatism</i> , 2005, 52, 911-915.	6.7	164
234	Involvement of chemokines and type 1 cytokines in the pathogenesis of hepatitis C virus-associated mixed cryoglobulinemia vasculitis neuropathy. <i>Arthritis and Rheumatism</i> , 2005, 52, 2917-2925.	6.7	76

#	ARTICLE	IF	CITATIONS
235	Severe pulmonary arterial hypertension as initial manifestation of intravascular lymphoma: Case report. American Journal of Hematology, 2005, 79, 46-49.	4.1	31
236	Hepatitis B virus genotypes and extrahepatic manifestations. Journal of Hepatology, 2005, 43, 764-770.	3.7	104
237	Treatment with Peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia. Journal of Hepatology, 2005, 43, 737.	3.7	4
238	Central nervous system involvement in hepatitis C virus cryoglobulinemia vasculitis: a multicenter case-control study using magnetic resonance imaging and neuropsychological tests. Journal of Rheumatology, 2005, 32, 484-8.	2.0	68
239	Treatment of hepatitis C virus-related systemic vasculitis. Journal of Rheumatology, 2005, 32, 2078-82.	2.0	13
240	Predominance of type 1 (Th1) cytokine production in the liver of patients with HCV-associated mixed cryoglobulinemia vasculitis. Journal of Hepatology, 2004, 41, 1031-1037.	3.7	47
241	CD4+CD25+ regulatory T-cell deficiency in patients with hepatitis C-mixed cryoglobulinemia vasculitis. Blood, 2004, 103, 3428-3430.	1.4	207
242	Chronic Lithium Nephropathy: MR Imaging for Diagnosis. Radiology, 2003, 229, 570-574.	7.3	97
243	Vascular Behçet's disease: a comparative study from Turkey and France. Clinical and Experimental Rheumatology, 0, , .	0.8	1